<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831922</url>
  </required_header>
  <id_info>
    <org_study_id>AB04012</org_study_id>
    <nct_id>NCT00831922</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis</brief_title>
  <official_title>A Multicenter, Open Label, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis With Inadequate Response to at Least One Disease Modifying Anti Rheumatic Drugs (DMARD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the activity of 2 oral doses of AB1010 in subjects
      suffering from active RA who have shown an inadequate response to one DMARD including MTX or
      anti-TNF, after 3 months (12 weeks) of treatment.

      The safety and efficacy will be evaluated on:

      Rate of patients achieving ACR 20, 50, 70 and 90 DAS (disease activity score) after 3 months
      treatment ACRn after 3 months treatment Therapeutic maintenance of AB1010 at 3 months Quality
      of Life assessed by SF12 Health Assessment Questionnaire (HAQ) Clinical and biological safety
      Pharmacokinetic profile of AB1010
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of patients achieving ACR 20, 50, 70 and 90 at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAS (disease activity score) at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACRn at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of quality of life assessed by SF12 at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib (AB1010) 3 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib (AB1010) 6 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib (AB1010)</intervention_name>
    <description>3 mg/kg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib (AB1010)</intervention_name>
    <description>6 mg/kg/day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meet American College of Rheumatology (ACR) criteria for RA

          2. Have active RA

          3. ACR functional class I-III

          4. Disease onset at &gt; 16 years of age

          5. Disease duration of at least 6 months

          6. Failure to one DMARD including methotrexate and anti-TNF alpha

        Exclusion Criteria:

          1. Pregnant or breastfeeding women

          2. Inadequate bone marrow function

          3. Current use of a DMARD within 4 weeks (or 5 half-lives, whichever is longer) of
             screening except for leflunomide which requires a specific wash-out

          4. Any previous use of recombinant IL1-Ra

          5. Current use of more than 1 non steroidal anti-inflammatory drug (NSAID) or change of
             dose of the NSAID within 4 weeks of baseline or NSAID use greater than the maximum
             recommended dose

          6. Within 4 weeks before baseline, use of more than 10 mg/day of prednisone or equivalent
             or change in the dose of prednisone or equivalent, or having intra-articular
             corticosteroid injection or bolus intramuscular or intravenous treatment with
             corticosteroids (&gt;20 mg prednisone or equivalent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Mariette, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Kremlin Bicêtre, France</affiliation>
  </overall_official>
  <link>
    <url>http://arthritis-research.com/content/11/3/R95</url>
    <description>Publication on study results</description>
  </link>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2009</study_first_submitted>
  <study_first_submitted_qc>January 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2009</study_first_posted>
  <last_update_submitted>August 11, 2009</last_update_submitted>
  <last_update_submitted_qc>August 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alain Moussy</name_title>
    <organization>AB Science</organization>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>DMARD failure</keyword>
  <keyword>ACR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

